about
2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of theThe new kids on the block of arrhythmogenic disorders: Short QT Syndrome and early repolarization.Clinical Challenges in Catecholaminergic Polymorphic Ventricular Tachycardia.UceWeb: a web-based collaborative tool for collecting and sharing quality of life data.Long-term follow-up of patients with short QT syndrome.Programmed Ventricular Stimulation for Risk Stratification in the Brugada Syndrome: A Pooled Analysis.Gene-Specific Therapy With Mexiletine Reduces Arrhythmic Events in Patients With Long QT Syndrome Type 3.Arrhythmogenic Right Ventricular Cardiomyopathy: Clinical Course and Predictors of Arrhythmic Risk.Phenotype and prognostic correlations of the converter region mutations affecting the β myosin heavy chainNovel insight into the natural history of short QT syndrome.The usual suspects in sudden cardiac death of the young: a focus on inherited arrhythmogenic diseases.Gquest: modeling patient questionnaires and administering them through a mobile platform application.Genetic causes of sudden cardiac death in children: inherited arrhythmogenic diseases.Genetic causes of sudden cardiac death in the young.Is There a Role for Genetics in the Prevention of Sudden Cardiac Death?Allele-Specific Silencing of Mutant mRNA Rescues Ultrastructural and Arrhythmic Phenotype in Mice Carriers of the R4496C Mutation in the Ryanodine Receptor Gene (RYR2).Hydroquinidine Prevents Life-Threatening Arrhythmic Events in Patients With Short QT Syndrome.Diagnosis of Long QT Syndrome: Time to Stand Up!Graphical representation of life paths to better convey results of decision models to patients.Clinical Presentation and Outcome of Brugada Syndrome Diagnosed With the New 2013 Criteria."Ten Commandments" of 2015 European Society of Cardiology Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death.Genotype-dependent differences in age of manifestation and arrhythmia complications in short QT syndrome.From decision to shared-decision: Introducing patients' preferences into clinical decision analysis.Brugada Syndrome: The Endless Conundrum.Short QT Syndromes.2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac deathInterplay Between Genetic Substrate, QTc Duration, and Arrhythmia Risk in Patients With Long QT SyndromeCardioVAI: An automatic implementation of ACMG-AMP variant interpretation guidelines in the diagnosis of cardiovascular diseasesGuía ESC 2015 sobre el tratamiento de pacientes con arritmiasventriculares y prevención de la muerte súbita cardiacaUsefulness of exercise test in the diagnosis of short QT syndromeMolecular autopsy for sudden unexplained death? Time to discuss pros and cons[2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death]Genetic risk stratification in cardiac arrhythmiasThe Phenotypic Spectrum of a Mutation Hotspot Responsible for the Short QT SyndromeReply: Did Mutation Type Affect the Efficacy of Mexiletine Observed in Patients With LQTS Type 3?Predicting Patient Response to the Antiarrhythmic Mexiletine Based on Genetic Variation
P50
Q28087002-4B0381C4-A2EF-43FD-9E03-FB855AF7B266Q30234301-1C59F93F-7FC3-44A9-AB3F-3F3F35861DF9Q30251824-1BD12862-FCF9-403B-83F0-9E8D9173F4D4Q30866700-99EF8F26-9574-41BB-9825-0BA58CF5E932Q33160301-C4233742-98D7-4290-AFDE-27CEE657CD9EQ33166717-97C0EEB3-A06E-4664-A750-AC85DA9FFB27Q33166896-4090CBF8-0795-4CF2-B543-EE82EB07DB65Q33167985-44F42158-57B8-42A4-AA1E-09A10CC68F57Q35792948-DC874D9C-2E0B-45F0-9ADB-BAD196AC1D0FQ37706496-DA3FB017-6EBE-4F55-95D0-EF0F60731EA0Q38197734-4C455AE3-A52B-4629-B056-BD14BDC0A4A0Q38416367-A866AAAF-2B49-4521-829E-6A99E99E4855Q38651712-70F751D8-28F2-45A5-ADFA-A6EE199A9224Q38749716-E514EBF7-43A4-494D-B9F8-4BFEED13203DQ38856035-D3EDB1F6-72B2-4B30-B3F1-BC0B612547BBQ40157909-28BA3CA9-E0B6-462E-A6A0-0594B5E17865Q47249207-7232A981-15DF-402F-B32E-EB69D4A903F3Q50590950-682F8080-2316-4877-AE2C-FCC1665093C1Q50974157-8FB72DE1-E7F6-408F-9476-2E4E0ABB0154Q51306853-27756E19-7CFA-4073-965E-0757C67D9231Q51346146-1220956A-4A4B-44D2-B24F-F941CD625A3BQ51631345-32E45200-33AC-4E5E-B0A7-7A47E428E9AEQ51767948-06914BAB-7406-4A66-8FE9-0F7EB27258F9Q54273342-1D45C354-55F7-4124-961E-A3EC333769FDQ54772916-706EAC04-322A-4FB8-ABC2-5FFD6BDEA8FBQ55983200-E0A6DA59-54FF-40B3-B5C5-A52B37C8F2B1Q56032608-83CCD3AB-ED41-4876-B7D0-8B0CC3BCCF51Q57288812-46571253-D8A0-4B9F-9DF6-9CF9A452FF3CQ57626389-6A89633E-5F04-43F8-A1CF-3DA0666C9CEDQ59490127-E5406B88-96EC-4C6B-8DA5-48592532BE27Q84960534-BB89223E-C122-4C21-8B5D-D77C332D49F8Q88174109-E28E11AE-D259-4840-AAD0-E7E94B9E28CBQ88291358-0187740A-90C4-4B4A-B89C-9B65EFD9DE41Q88668245-3BE1D57C-ACE6-4662-AC74-52356DB5FF93Q89910322-C05B870A-7752-4345-8DFA-5156FFD164E7Q90632675-9571B14A-8590-42FC-B318-03BBB02DAFAA
P50
description
onderzoeker
@nl
researcher, ORCID id # 0000-0002-0208-2172
@en
name
Andrea Mazzanti
@ast
Andrea Mazzanti
@en
Andrea Mazzanti
@es
Andrea Mazzanti
@nl
type
label
Andrea Mazzanti
@ast
Andrea Mazzanti
@en
Andrea Mazzanti
@es
Andrea Mazzanti
@nl
prefLabel
Andrea Mazzanti
@ast
Andrea Mazzanti
@en
Andrea Mazzanti
@es
Andrea Mazzanti
@nl
P106
P1153
36480298200
P31
P496
0000-0002-0208-2172